{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=98", "query": { "condition": "Lymphoma", "page": 98 }, "page_size": 10 }, "pagination": { "page": 98, "page_size": 10, "total_count": 5759, "total_pages": 576, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=99&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=97&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T11:41:48.752Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02542124", "title": "NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous T Cell Lymphoma (CTCL)", "Mycosis Fungoides", "Sézary Syndrome" ], "interventions": [ { "name": "NM-IL-12 and TSEBT", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Neumedicines Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-12", "completion_date": "2019-05", "has_results": false, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-11-05T11:41:48.752Z", "location_count": 3, "location_summary": "Stanford, California • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02542124" }, { "nct_id": "NCT05283720", "title": "A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Epcoritamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride [HCl]", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "CC-99282", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 264, "start_date": "2022-06-14", "completion_date": "2032-11", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-11-05T11:41:48.752Z", "location_count": 18, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05283720" }, { "nct_id": "NCT00289562", "title": "Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "forodesine hydrochloride (BCX-1777)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCryst Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20, "start_date": "2004-09", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2012-01-20", "last_synced_at": "2026-11-05T11:41:48.752Z", "location_count": 7, "location_summary": "Denver, Colorado • Chicago, Illinois • Kansas City, Kansas + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00289562" }, { "nct_id": "NCT00136474", "title": "Amifostine for Head and Neck Irradiation in Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Hodgkin's Disease", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Amifostine", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 75, "start_date": "2003-05", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2009-11-02", "last_synced_at": "2026-11-05T11:41:48.752Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00136474" }, { "nct_id": "NCT02489123", "title": "Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage I Mantle Cell Lymphoma", "Ann Arbor Stage II Mantle Cell Lymphoma", "Ann Arbor Stage III Mantle Cell Lymphoma", "Ann Arbor Stage IV Mantle Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2015-08-11", "completion_date": "2020-06-16", "has_results": true, "last_update_posted_date": "2021-08-10", "last_synced_at": "2026-11-05T11:41:48.752Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02489123" }, { "nct_id": "NCT01282476", "title": "Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "Panobinostat with Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2011-06", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-11-05T11:41:48.752Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01282476" }, { "nct_id": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma", "Gastric Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "EGFR Positive Solid Tumor", "HER2-positive Breast Cancer", "Hepatocellular Carcinoma", "Small Cell Lung Cancer", "Renal Cell Carcinoma", "Pancreas Cancer", "Melanoma", "NSCLC", "Urothelial Carcinoma", "Cervical Cancer", "Microsatellite Instability", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "FT500", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2019-02-15", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2023-05-01", "last_synced_at": "2026-11-05T11:41:48.752Z", "location_count": 4, "location_summary": "San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03841110" }, { "nct_id": "NCT00512460", "title": "RTA 744 Injection in Patients With Leptomeningeal Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplastic Meningitis", "Solid Tumor", "Lymphoma", "Leukemia", "Brain Tumor" ], "interventions": [ { "name": "RTA 744", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2006-09", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2016-05-16", "last_synced_at": "2026-11-05T11:41:48.752Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00512460" }, { "nct_id": "NCT01776840", "title": "A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 523, "start_date": "2013-05-16", "completion_date": "2024-06-24", "has_results": true, "last_update_posted_date": "2025-07-08", "last_synced_at": "2026-11-05T11:41:48.752Z", "location_count": 44, "location_summary": "Tucson, Arizona • Burbank, California • La Jolla, California + 41 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01776840" }, { "nct_id": "NCT00002750", "title": "Melphalan in Patients With Neoplastic Meningitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Extragonadal Germ Cell Tumor", "Leukemia", "Lymphoma", "Ovarian Cancer" ], "interventions": [ { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 6, "start_date": "1992-12", "completion_date": "2001-05", "has_results": false, "last_update_posted_date": "2013-02-20", "last_synced_at": "2026-11-05T11:41:48.752Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002750" } ] }